Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA.
2005.
Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.. Cancer Res. 65(13):5750-60.
Hofer MD, Browne TJ, He L, Skotheim RI, Lothe RA, Rubin MA.
2005.
Identification of two molecular groups of seminomas by using expression and tissue microarrays.. Clin Cancer Res. 11(16):5722-9.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..
2005.
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..
2005.
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.
Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.
2007.
Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.
Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.
2005.
Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.
Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM et al..
2004.
JAGGED1 expression is associated with prostate cancer metastasis and recurrence.. Cancer Res. 64(19):6854-7.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..
2015.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol. 26(8):1589-604.
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..
2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.
Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK et al..
2012.
Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.. Diagn Mol Pathol. 21(2):61-8.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..
2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.